Scholarly works in Clinical Pharmacy & Administration

Permanent URI for this collectionhttps://repository.ibadanedu.com/handle/123456789/383

Browse

Subject: search.filters.subject.Hibiscus sabdariffa

Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Safety Evaluation of Hibiscus sabdariffa Tea and its Effect on Blood Pressure, Blood Glucose and Lipid Profile: A Randomised Controlled Trial.
    (EManuscript Services, 2021) Showande, J.S.; Dede, A.I; Fakeye T.O.
    Background: Hibiscus sabdariffa lowers blood pressure, blood glucose and total cholesterol in patients yet healthy individuals widely consume the tea. This study evaluated the effect of Hibiscus sabdariffa tea (HS-tea) on clinical, biochemical and haematological parameters in healthy human volunteers. Materials and Methods: Thirty-two healthy human volunteers were randomized in a two-arm open-labelled parallel study into HS-tea (n=17) and Water group (n=15). Three hundred millilitre of either HS-tea or Water was taken daily for 28 days by the participant and clinical (Systolic blood pressure SBP, fasting blood glucose FBG, total cholesterol TC, etc.), biochemical (alanine aminotransferase ALT, albumin ALB, aspartate aminotransferase AST, Serum creatinine SCr, etc.) and haematological (haematocrit HCT, white blood cells count WBC, total protein TPro, etc.) parameters were measured at baseline and on the 14th and 28th day. Results: Daily intake of HS-tea reduced SBP (9.1%, p=0.008), FBG (8.0%, p=0.006) and TPro (5.8%) but increased WBC (34.3%) on the 28th day compared with baseline values. No change was observed with Water. HS-tea lowered SBP, FBG, TC and ALB significantly on the 28th day compared with Water. No significant difference between HS-tea and Water with liver and kidney function markers (AST, ALT, SCr) and haematological parameters (HCT, WBC, TPro). Conclusion: Daily intake of Hibiscus sabdariffa tea for 28 days is safe and reduced SBP, FBG, TC and ALB in healthy human volunteers. It may be considered as a potential nutraceutical candidate for people at risk of developing hypertension, diabetes and hypercholesterolemia.
  • Thumbnail Image
    Item
    Safety Evaluation of Hibiscus sabdariffa Tea and its Effect on Blood Pressure, Blood Glucose and Lipid Profile: A Randomised Controlled Trial.
    (EManuscript Services, 2021) Showande, J.S.; Dede, A.I; Fakeye T.O.
    Background: Hibiscus sabdariffa lowers blood pressure, blood glucose and total cholesterol in patients yet healthy individuals widely consume the tea. This study evaluated the effect of Hibiscus sabdariffa tea (HS-tea) on clinical, biochemical and haematological parameters in healthy human volunteers. Materials and Methods: Thirty-two healthy human volunteers were randomized in a two-arm open-labelled parallel study into HS-tea (n=17) and Water group (n=15). Three hundred millilitre of either HS-tea or Water was taken daily for 28 days by the participant and clinical (Systolic blood pressure SBP, fasting blood glucose FBG, total cholesterol TC, etc.), biochemical (alanine aminotransferase ALT, albumin ALB, aspartate aminotransferase AST, Serum creatinine SCr, etc.) and haematological (haematocrit HCT, white blood cells count WBC, total protein TPro, etc.) parameters were measured at baseline and on the 14th and 28th day. Results: Daily intake of HS-tea reduced SBP (9.1%, p=0.008), FBG (8.0%, p=0.006) and TPro (5.8%) but increased WBC (34.3%) on the 28th day compared with baseline values. No change was observed with Water. HS-tea lowered SBP, FBG, TC and ALB significantly on the 28th day compared with Water. No significant difference between HS-tea and Water with liver and kidney function markers (AST, ALT, SCr) and haematological parameters (HCT, WBC, TPro). Conclusion: Daily intake of Hibiscus sabdariffa tea for 28 days is safe and reduced SBP, FBG, TC and ALB in healthy human volunteers. It may be considered as a potential nutraceutical candidate for people at risk of developing hypertension, diabetes and hypercholesterolemia
  • Thumbnail Image
    Item
    Pattern of Use of Water Beverage of Hibiscus sabdariffa Linn in a University Community in Southwest Nigeria.
    (West African Postgraduate College of Pharmacists (WAPCP),, 2017) Showande, J.S.; Udoh-Kalu, C.C.; Fakeye, T.O
    Background:Water beverages of Hibiscus sabdariffa is widely consumed in many parts of the world. Objective: Its pattern of use in a University community in southwest Nigeria was studied. Methods: A questionnaire-guided survey was conducted among randomly selected staff (398) and students (910) of University of Ibadan on the use of water beverage of Hibiscus sabdariffa (WBHS). The questionnaire garnered information on pattern of use, side effects experienced, and drugs coadministered with WBHS. Descriptive statistics, Chi-square, and Fisher's Exact Probability tests were used to describe the association between categories of participants and indications for using and side effects experienced with WHBS. Results: Most (96.9%) respondents who had used WBHS, used it as a relaxant 382(29.2%), as an antihypertensive 318(24.3%), for weight reduction 140(10.7%), infertility 127(9.7%), to cure liver disease 87(6.7%), and for the management of diabetes 151(11.5%). Side effects experienced with its use were; diarrhea 69(5.3), dizziness 44(3.4%), insomnia 27 (2.1%), decreased libido 24(1.8%), blurred vision 16(1.2%),and headache 19(1.5%).Some of the participants 164(12.5%) coadministered WBHS with their medications such as antibiotics 51(3.9%), antihypertensives 24(1.8%), antipsychotic 18(1.4%), antilipidemic drugs 16(1.2%), and antiretroviral drugs 11(0.8%). Out of those who coadministered WBHS with their medications, 93(7.1%) were on chronic medications. Conclusion: Water beverage of Hibiscus sabdariffa is used to treat diverse diseases with attendant side effects and is sometimes coadministered with medications for chronic diseases. This may predispose users to herb-drug interactions. Thus there is a need to investigate some of the drugs co-administered with the beverage for possible herb-drug interaction.
  • Thumbnail Image
    Item
    In Vitro Modulation Of Cytochrome P450 Isozymes And Pharmacokinetics Of Caffeine By Extracts Of Hibiscus Sabdariffa Linn Calyx
    (2019) Showande S.J; Igbinoba S.I.; Kajula M.; Hokkanen J.; Tolonen A.; |Adegbolagun O.M.; Fakeye T.O.
    Background: Hibiscus sabdariffa beverage (HSB) is widely consumed as a medicinal herb and sometimes used concomitantly with drugs. This study evaluated the in vitro inhibitory potential of the aqueous extract of H. sabdariffa calyces (AEHS) on selected cytochrome P450 (CYP) isozymes and the effect of HSB on the pharmacokineticsofcaffeineinvivo. Methods:InvitroinhibitionsofeightmajorCYPisozymesbyAEHSwereestimatedbymonitoringCYP-specific modelreactionsof10CYPprobesubstratesusingN-in-oneassaymethod.Subsequently,anopen,randomized, two-periodcrossoverdesignwasusedtoevaluatetheeffectofHSBonthepharmacokineticsofsingle-dose200 mg caffeine in six healthy human volunteers. Blood samples were obtained at specific times over a 24 h period. Probe drugs and metabolites were analyzed in their respective matrices with ultra-performance liquid chromatography/mass spectrometer/mass spectrometer and reversed-phase high-performance liquid chromatography/ultravioletdetection. Results:TheH.sabdariffaaqueousextractweaklyinhibitedtheselectedCYPisozymesinvitro,withIC50of >100 μgmL-1 intheorderofCYP1A2>CYP2C8>CYP2B6»CYP2D6>CYP2C19>CYP3A4>CYP2A6>CYP2C9. HSBdecreasedterminalt1/2andTmaxofcaffeineby13.6%and13.0%,respectively,andincreasedCmaxby10.3%. Pointestimatesofprimarypharmacokineticendpoints,Cmax=1.142(90%confidenceinterval(CI)=0.882,1.480) andAUC0–∞=0.992(90%CI=0.745,1.320),wereoutsidethe90%CIof0.8–1.25bioequivalencelimits. Conclusion:TheaqueousextractofH.sabdariffaweaklyinhibitedeightCYPisozymesinvitro,butHSBmodified theexposuretocaffeineinhuman.CautionshouldbeexercisedinadministeringHSBwithcaffeineorsimilar substratesofCYP1A2untilmoreclinicaldataareavailable.
  • Thumbnail Image
    Item
    In vitro inhibitory activities of the extract of hibiscus sabdariffa l.
    (2013) Showande S.J.; Fakeye T.O; Tolonen A; Hokkanen J.
    Literature is scanty on the interaction potential of Hibiscus sabdariffa L., plant extract with other drugs and the affected targets. This study was conducted to investigate the cytochrome P450 (CYP) isoforms that are inhibited by the extract of Hibiscus sabdariffa L. in vitro. The inhibition towards the major drug metabolizing CYP isoforms by the plant extract were estimated in human liver microsomal incubations, by monitoring the CYP-specific model reactions through previously validated N-in-one assay method. The ethanolic extract of Hibiscus sabdariffa showed inhibitory activities against nine selected CYP isoforms: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. The concentrations of the extract which produced 50% inhibition of the CYP isoforms ranged from 306 µg/ml to 1660 µg/ml, and the degree of inhibition based on the IC50 values for each CYP isoform was in the following order: CYP1A2 > CYP2C8 > CYP2D6 > CYP2B6 > CYP2E1 > CYP2C19 > CYP3A4 >> CYP2C9 >> CYP2A6. Ethanolic extract of Hibiscus sabdariffa caused inhibition of CYP isoforms in vitro. These observed inhibitions may not cause clinically significant herb-drug interactions; however, caution may need to be taken in co-administering the water extract of Hibiscus sabdariffa with other drugs until clinical studies are available to further clarify these findings.